We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Changes In Lymphatic Vessels Can Aid Early Identification of Aggressive Oral Cancer

By LabMedica International staff writers
Posted on 23 Feb 2026

Oral cancers are the most common malignant tumors in the head and neck region and cause more than 188,000 deaths worldwide each year. More...

Unlike many other cancers, even small, early-stage oral tumors can be life-threatening. In Finland, up to one in five patients treated at an early stage later die from the disease. Researchers have now identified a biological marker within tumor lymphatic vessels that may help detect high-risk oral cancers at diagnosis.

In a study conducted by researchers at the University of Turku (Turku, Finland), the team analyzed early-stage oral cancer samples from approximately 300 Finnish patients, focusing on defense and structural cells within tumor tissue. By examining multiple protein markers, the researchers identified an unexpected pattern: certain tumors contained an unusually high number of proliferating lymphatic vessels. In healthy oral tissue, lymphatic vessel cells rarely divide and do not typically express proteins linked to cell division.

Tumors with a higher number of proliferating lymphatic vessels were strongly associated with cancer recurrence and mortality. The presence of these dividing lymphatic vessel cells predicted disease progression more accurately than previously established risk factors for oral cancer. The findings, published in Cell Reports Medicine, suggest that assessing these protein markers in lymphatic vessel surface cells could help identify aggressive forms of oral cancer at an early stage.

Early identification of high-risk tumors may allow clinicians to tailor treatment strategies more precisely. Currently, oral cancer treatment primarily involves surgery, and there are limited tools for guiding adjuvant therapy decisions. Researchers believe the newly identified marker could serve as a practical clinical tool and are interested in exploring whether it has similar predictive value in other cancer types.

“We are excited about the results and believe that the findings could also be applied as a practical tool for clinical use,” said the lead author of the study Joni Näsiaho. “Furthermore, it would be interesting to find out whether the marker we discovered has a similar predictive value in other cancer groups.”

Related Links:
University of Turku


Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology Analyzer
Medonic M32B
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The partnership with LLS expands access to Lucent’s non-invasive blood-based biomarker tests for early detection of cognitive diseases (photo courtesy of Adobe Stock)

New Partnership Brings Alzheimer’s Blood Biomarker Test to Community Screening Network

Lucent Diagnostics, a brand of Quanterix Corporation, has partnered with Life Line Screening (LLS) to offer Lucent’s non‑invasive, blood‑based biomarker test across the United States. Programs are... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.